Skip to main content

BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)

Tipranks - Tipranks - Sat Feb 21, 11:16AM CST

BTIG analyst Marie Thibault maintained a Buy rating on Boston Scientific on February 18 and set a price target of $110.00.

President's Day Sale - 70% Off

According to TipRanks, Thibault is an analyst with an average return of -12.6% and a 33.53% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Ceribell, Inc., and Boston Scientific.

In addition to BTIG, Boston Scientific also received a Buy from Needham’s Michael Matson in a report issued on February 18. However, on the same day, TipRanks – xAI reiterated a Hold rating on Boston Scientific (NYSE: BSX).

See the top stocks recommended by analysts >>

Based on Boston Scientific’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.07 billion and a net profit of $755 million. In comparison, last year the company earned a revenue of $4.21 billion and had a net profit of $469 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).